Short- and long-term efficacy

European Respiratory Journal, Supplement

Volumn 12, Issue 27, 1998, Pages

  Wennergren, G ^a   Wilson, N ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Asthma; Children; Early intervention; Efficacy measurements; Outcomes

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOCHEMICAL MARKER; BRONCHODILATING AGENT; BUDESONIDE; CETIRIZINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; THEOPHYLLINE;

ASTHMA; CHILD; CHILDHOOD DISEASE; CLINICAL STUDY; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; HISTORY; HUMAN; LUNG FUNCTION; MEASUREMENT; MORBIDITY; PRIORITY JOURNAL; QUALITY OF LIFE; SYMPTOM; TREATMENT OUTCOME; TYPES OF STUDY; WHEEZING; METHODOLOGY; PRESCHOOL CHILD; REVIEW; TIME;

ASTHMA; CHILD; CHILD, PRESCHOOL; HUMANS; MORBIDITY; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032114240     PISSN: 09041850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Silverman M, Pedersen S, eds. Outcome measures in early childhood asthma and other wheezing disorders. Eur Respir J 1996; 9: Suppl 21, 1s-49s.
2. Rosier MJ, Bishop J, Nolan T. Measurement of functional severity of asthma m children. Am J Respir Crit Care Med 1994; 149: 1434-1441.
3. O'Connor GT, Weiss ST. Clinical and symptom measurement. Am J Respir Crit Care Med 1994; 149: S21-S28.
4. Steen N, Hutchinson A, McCole E, et al. Development of a symptom based outcome measure for asthma. BMJ 1994; 309: 1065-1068.
5. Santanello NC, Barber BL, Reiss BS, et al. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J 1997; 10: 646-651.
6. Hyland ME, Crocker GR. Validation of an asthma quality of life diary in a clinical trial. Thorax 1995; 50; 724-730.
7. Bucknall CE. Definitions of severity and outcome measures. Respir Med 1996; 90: 447-452.
8. Wilson NM, Doré C, Silverman M. Wheezing in 5 year old children: factors related to severity. Eur Respir J 1997; 10: 346-353.
9. Wilson N, Sloper K, Silverman M. Effect of continuous treatment with topical corticosteroids on episodic viral wheeze in preschool children. Arch Dis Child 1995; 72: 317-320.
10. Christie MJ, French D, Sowden A, West A. Development of child-centered disease-specific questionnaire for living with asthma. Psychosom Med 1993; 55: 541-548.
11. Juniper EF, Guyatt GH, Feeny DH, et al. Measuring quality of life in children with asthma. Qual Life Res 1996; 155: 487-492.
12. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373-381.
13. Kristjánsson S, Strannegård IL, Strannegård Ö, Peterson C, Enander I, Wennergren G. Urinary eosinophil protein X (EPX) in children with atopic asthma. A useful marker of antiinflammatory treatment. J Allergy Clin Immunol 1996; 97: 1179-1187.
14. Apter AJ, ZuWallack RL, Clive J. Common measures of asthma severity lack association for describing its clinical course. J Allergy Clin Immunol 1994; 94: 732-737.
15. McFadden ER. Clinical and physiological correlates in asthma. J Allergy Clin Immunol 1986; 77: 1-5.
16. Wennergren G, Nordvall SL, Hedlin G, Möller C, Wille S, Åsbrink Nilsson E. Nebulized budesonide for the treatment of moderate to severe asthma in infants and toddlers. Acta Paediatr 1996; 85: 183-189.
17. Carlsen K-H, Leegard J, Larsen S, Ørstavik I. Nebulised beclomethasone in recurrent obstructive episodes after acute bronchiolitis. Arch Dis Child 1989; 63: 1428-1433.
18. Wilson NM, van Bever H. Overall symptom measurement: which approach? Eur Respir J 1996; 9: Suppl 21, 8s-11s.
19. Johnston SL, Pattemore PK, Sanderson G, et al. A community study of the role of virus infections in exacerbations of asthma in 9-11 year old children. BMJ 1995; 310: 1225-1229.
20. Connolly CK, Prescott RS, Alcock SM, Galnash AA. Actual over best as an outcome measure in asthma. Respir Med 1994; 88: 453-459.
21. Toogood JH, Andreou P, Baskerville J. A methodological assessment of diurnal variability of peak flow as a basis for comparing different inhaled steroid formulations. J Allergy Clin Immunol 1996; 98: 555-562.
22. Platts-Mills TAE, Mitchell EB, Nock P, Tovey ER, Moszoro H, Wilkins SR. Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet 1982; ii: 675-678.